Soft Tissue Sarcoma Treatment Market: By Treatment Type (Targeted Therapy, Chemotherapy, Anti-angiogenesis drugs, Radiation Therapy, Internal Radiation Therapy, External Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Long-Term Care Centres) and Geography  

Soft Tissue Sarcoma Treatment Market size was valued at 3,595.4 million in 2022 and is poised to grow at a CAGR of 7.3%  from 2023 to 2029. Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used. Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all ifosfamide development expenses. GSK's Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as a first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.